SCIDOT-30. GLITIPNI: A PHASE 1B CLINICAL TRIAL COMBINING SURGICAL RESECTION WITH DIRECT INTRACEREBRAL INJECTION OF IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH RECURRENT GLIOBLASTOMA

INTRODUCTION: Intravenous (iv) administration of PD-1 blocking mAb is largely ineffective for the treatment of recurrent glioblastoma (rGB). Combination of iv-ipilimumab (IPI) plus nivolumab (NIVO) is associated with a high incidence of irAE. Intracerebral (ic) administration of immune-checkpoint in...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neuro Oncol
Autori principali: Duerinck, Johnny, Awada, Gil, Katharina Schwarze, Julia, Dufait, Ines, Peeters, Stephanie, Seynaeve, Laura, Van Binst, Anne-Marie, Everaert, Hendrik, Michotte, Alex, Rogiers, Anne, Van Velthoven, Vera, Neyns, Bart
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2019
Soggetti:
Abstracts from the 3rd Sno-Scidot Joint Conference on Therapeutic Delivery to the CNS
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6846145/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.1166
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi